Search Results

Guardant Health, Inc., a leading precision oncology company, announced the launch of a new version of its Guardant360 TissueNext test that expands the number of genes it identifies in a tumor tissue sample to 498.

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will participate in the following investor conferences.

Guardant Health, Inc., a leading precision oncology company, announced the company will participate in the following investor conferences.

Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced its inclusion in the fourth-annual TIME100 Most Influential Companies list, highlighting companies making an extraordinary impact around the world.

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced certification for its Guardant360® CDx blood test under the European Union’s In Vitro Diagnostic Regulation (IVDR 2017/746).

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that on April 22, 2024, the Compensation Committee of Guardant’s Board of Directors approved the granting of restricted stock units (“RSUs”) representing 215,601 shares of its common stock to 94 new non-executive employees and non-qualified stock option awards to purchase an aggregate of 98,076 shares of its common stock to three new non-executive employees.

Guardant Health, Inc., a leading precision oncology company, reported financial results for the quarter ended March 31, 2024.

Guardant Health, Inc. today announced the company and its research collaborators will present data from 16 studies highlighting the role of Guardant blood tests and real-world data in advancing precision oncology and cancer screening at the 2024 American Society for Clinical Oncology (ASCO) Annual Meeting, May 31-June 4 in Chicago.

Guardant Health, Inc. today announced the Molecular and Clinical Genetics Panel of the U.S. Food and Drug Administration Medical Devices Advisory Committee is scheduled to review the premarket approval (PMA) application for the company’s Shield™ blood test for colorectal cancer (CRC) screening on Thursday, May 23, 2024.

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will present data from two real-world studies at the 2024 Digestive Disease Week (DDW) meeting in Washington, DC, highlighting the value of the company’s Shield™ test in colorectal cancer (CRC) screening.